Antibiotic treatment strategies for Helicobacter pylori infection

Recent Patents on Anti-Infective Drug Discovery

Volumn 2, Issue 1, 2007, Pages 11-17

  Campo, Salvatore M A ^a   Zullo, A ^a   Hassan, C ^a   Morini, S ^a  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

Author keywords

Antibiotics; Helicobacter pylori; Therapy

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BISMUTH CITRATE; BISMUTH SALICYLATE; BISMUTH SALT; CLARITHROMYCIN; ERYTHROMYCIN; FURAZOLIDONE; GARENOXACIN; IMIDAZOLE; KANAMYCIN; LEVOFLOXACIN; MACROLIDE; METRONIDAZOLE; MINOCYCLINE; MOXIFLOXACIN; NIFURATEL; NITROFURAN; NITROIMIDAZOLE; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BONE MARROW TOXICITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IN VITRO STUDY; META ANALYSIS; MONOTHERAPY; NEUROTOXICITY; NONHUMAN; PATENT; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-BACTERIAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; PATENTS AS TOPIC; STOMACH ULCER;

EID: 34248163570     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489107779561706     Document Type: Review

References (80)

1. Vaira D, Gatta L, Ricci C, D'Anna L, Miglioli M. Helicobacter pylori: diseases, tests and treatment. Dig Liver Dis 2001; 33: 788-94.
2. Bayerdorfer E, Morgner A. Gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: management of the disease. Dig Liver Dis 2000; 32: 192-94.
3. Nardone G. Risk factor of cancer development in Helicobacter pylori gastritis. Dig Liver Dis 2000; 32(Suppl. 1): 190-92.
4. Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98: 2621-26.
5. Abraham NS, Moayyedi P, Daniels B, Veldhuyzen Van Zanten SJ. Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment Pharmacol Ther 2004; 19: 631-41.
6. Lassen AT, Halas J, Schaffalittzky De Muckadell OB. Helicobacter pylori test and eradication versus prompt endoscopy for management of dyspeptic patients: 6.7 years follow-up of a randomised trial. Gut 2004; 53: 1758-63.
7. Backert S, Schwartz T, Miehlke S, et al. Functional analysis of the cag pathogenicity island in Helicobacter pylori isolates from patients with gastritis, peptic ulcer, and gastric cancer. Infect Immun 2004; 72: 1043-56.
8. Zullo A, Rinaldi V, Hassan C, Lauria V, Attili AF. Gastric pathology in cholecystectomy patients: role of Helicobacter pylori and bile reflux. J Clin Gastroenterol 1998; 27: 335-38.
9. Dzierzanowska-Fangrat K, Crabtree JE, Rozynek E, et al. Helicobacter pylori cagA genotype and density of colonization in relation to gastric inflammation in children. Eur J Gastroenterol Hepatol 2002; 14: 1303-07.
10. Ricci V, Zarrilli R, Romano M. Voyage of Helicobacter pylori in human stomach: odyssey of a bacterium. Dig Liver Dis 2002; 34: 2-8.
11. Caselli M, Parente F, Palli D, et al. Cervia Working Group Report: guidelines on the diagnosis and treatment of Helicobacter pylori infection. Dig Liver Dis 2001; 33: 75-80.
12. Sutton P, Doidge C. Helicobacter pylori vaccines spiral into the new millenium. Dig Liver Dis 2003; 35: 675-87.
13. Roos D, Weenings RS, Voetmann AA. Protection of human neutrophils by endogenous catalane. J Clin Invest 1980; 65: 1515-22.
14. De Francesco V, Zullo A, Margiotta M, et al. Sequential treatment for Helicobacter pylori infection does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004; 19: 407-14.
15. Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002. Dig Liver Dis 2003; 35: 541-45.
16. De Francesco V, Margotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006: 144: 94-100.
17. Zullo A, Hassan C, Morini S. Helicobacter pylori infection: to culture or not to culture? Dig Liver Dis 2003; 35: 357-61.
18. Lambert JR. Pharmacology of the gastric mucosa: a rational approach to Helicobacter polytherapy. Gastroenterology 1996; 111: 521-23.
19. Scarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis 2004; 36: 234-47.
20. Uunge P. Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol 1996; 31: 74-81.
21. Goddar AF, Jessa MJ, Barrett DA, et al. Effect of omeprazole on the distribution on metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996; 111: 358-67.
22. Paulsen IT, Brown MH, Skurray RA. Proton-dependent multidrug efflux systems. Microbiol Rev 1996; 60: 575-608.
23. Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 2003; 51: 9-11.
24. Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob, Agents 2002; 19: 67-70.
25. Realdi G, Dore MP, Piana A, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 1999; 4: 106-12.
26. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients. Int J Antimicrob Agents 2006; 28: 6-13.
27. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-84.
28. Graham DY, De Boer WA, Tytgat NNJ. Choosing the best anti- Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996; 91: 1072-76.
29. Irie Y, Tateda K, Matsumoto T, Miyazaki S, Yamaquchi K. Antibiotic MICs and short time-killing against Helicobacter pylori: therapeutic potential of kanamycin. J Antimicrob Chemother 1997; 40: 235-40.
30. Murakami K, Sato R, Okimoto T, et al. Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2006; 21: 262-67.
31. Nijevitch AA, Shcherbakov PL, Sataev VU, Khasanov RSH, Al Khashash R, Tuygunov MM. Helicobacter pylori eradication in childhood after failure of initial treatment: advantage of quadruple therapy with nifuratel to furazolidone. Aliment Pharmacol Ther 2005; 22: 881-87.
32. Datta S, Chattopadhyay S, Patra R, et al. Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. Aliment Pharmacol Ther 2005; 22: 51-57.
33. Su Z, Xu H, Zhang C, et al. Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance. Croat Med J 2006; 47: 410-15.
34. Marshall BJ. The use of bismuth in gastroenterology. Am J Gastroenterol 1991; 86: 16-25.
35. Malfertheiner P, Mégraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
36. Phillips RH, Whitehead MW, Doig LA, et al. Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe? Helicobacter 2001; 6: 151-56.
37. Koletzko S, Richy F, Bontems P, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut 2006 Apr 7; [Epub ahead of print].
38. Anagnostopoulos GK, Kostopoulos P, Margantinis G, Tsiakos S, Arvanitidis D. Omeprazole plus azithromycin and either amoxicillin or tinidazole for eradication of Helicobacter pylori infection. J Clin Gastroenterol 2003; 36: 325-28.
39. Tindberg Y, Casswall TH, Blennow M, Bengtsson C, Granstrom M, Sorberg M. Helicobacter pylori eradication in children and adolescents by a once daily 6-day treatment with or without a proton pump inhibitor in a double-blind randomized trial. Aliment Pharmacol Ther 2004; 20: 295-302.
40. Iacopini F, Crispino P, Paoluzi OA, et al. One-week once-daily triple therapy with esomeprazole, levofloxacin and azithromycin compared to a standard therapy for Helicobacter pylori eradication. Dig Liver Dis 2005; 37: 571-76.
41. Marshall BJ, Guerrant RL, Hoffman SR. Eradication of metronidazole resistant H. pylori. Am J Gastroenterol 1991; 86: 100-03.
42. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 1339-43.
43. Watanabe Y, Aoyama N, Shirasaka D, et al. Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 2003; 35: 711-15.
44. Marzio L, Coraggio D, Capodicasa S, Grossi L, Cappello G. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006; 11: 237-24.
45. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22: 45-49.
46. Zullo A, Hassan C, De Francesco V, et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 2003; 35: 232-36.
47. Gisbert JP, De La Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35-40.
48. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter py1ori infection: a meta-analysis. Am J Gastroenterol 2006; 101: 488-96.
49. Di Caro S, Ojetti V, Zocco MA, et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16: 527-32.
50. Nista EC, Candelli M, Zocco MA, et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2005; 21: 1241-47.
51. Cheon JH, Kim N, Lee DH. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 2006; 11: 46-51.
52. Gajjar DA, Bello A, Ge Z, Christopher L, Grasela DM. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 2003: 47: 2256-63.
53. Sharara AI, Chaar HF, Racoubian E, et al. Efficacy of two rabeprazole/gatifloxacin-based triple therapies for Helicobacter pylori infection. Halicobacter 2004; 9: 255-61.
54. Graham DY, Abudayyeh S, El-Zimaity HMT, Hoffman J, Reddy R, Operkun AR. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 24: 845-50.
55. Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimes. Aliment Pharmacol Ther 2004; 14: 311-16.
56. Toraccio S, Capodicasa S, Soraja DB, Cellini L, Marzio L. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005; 37: 33-38.
57. Borody TJ, Pang G, WEetstein AR, et al. Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006; 23: 481-88.
58. Canducci F, Ojetti V, Pola P, Gasbarrini G, Gasbarrini A. Rifabutin-based Helicobacter pylori eradication 'rescue therapy' Aliment Pharmacol Ther 2001; 15: 163-69.
59. Laheij RJ, Van Rossum LGM, Jansen JB, Straatman H, Verbeek AL. Evaluation of treatment regimens to cure Helicobacter pylori infection. A meta-analysis. Aliment Pharmacol Ther 1999; 13: 857-64.
60. Janssen MJR, Van Oijen Aham, Verbeek ALM, Jansen JBMJ, De Boer WA. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor /ranitidine bismuth citrate plus clarithromycin and either amoxycillin or a nitromidazole. Aliment Pharmacol Ther 2001; 15: 613-24.
61. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-08.
62. Gené E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: an updated meta-analysis. Aliment Pharmacol Ther 2003; 18: 543-44.
63. Zullo A, Rinaldi V, Winn S, et al. A new highly effective shortterm therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 715-18.
64. De Francesco V, Zullo A, Hassan C, et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig Liver Dis 2004; 36: 322-26.
65. Zullo A, VAaira D, Vakil N, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719-26.
66. Chalker, A.F., Minehart, H.W: WO0238156A (2002).
67. Sanchez JE, Saenz NG, Rincon MR, Martin IT, Sanchez EG, Martinez MJ. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J Antimicrob Chemother 2000; 46: 283-85.
68. Iwao E, Yokoyama Y, Yamamoto K, Hirayama F, Haga K, In vitro and in vivo anti-Helicobacter pylori activity of Y-904, a new fluoroquinolone. J Infect Chemother 2003; 9: 165-71.
69. Sugimori, G., Ohtsuka, T., Masui, M.: WO0240479A (2002).
70. Ascher, G., Hildebrandt, J: WO03090740 (2003).
71. Carcanague D, Shue YK, Wuonola, et al. Novel structures derived from 2- (2-pyridyl)mathyl]thio]-1H-benzimidazole as anti-Helicobacter pylori agents, Part 2. J Med Chem 2002; 45: 4300-09.
72. Kobayashi I, Muraoka H, Hasegawa M, et al. in vitro Anti- Helicobacter pylori activity of BAS-118, a new benzamide derivative. J Antimicrob Chemother 2002; 50: 129-32.
73. Hasuoka A, Nishikimi Y, Nakayama Y, et al. Synthesis and anti- Helicobacter pylori activity of pyloricidin derivatives II. The combination of amino acid residues in the dipeptidic moiety and its effect on the anti-Helicobacter pylori activity. J Antibiot 2002; 55: 499-507.
74. Katsura Y, Nshino S, Inoue Y, et al. Anti-Helicobacter pylori agents. 5.2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues. J Med Chem 2002; 45: 143-50.
75. Yoshida Y, Matsuda K, Sasaki H, et al. Studies on anti- Helicobacter pylori agents. Part 3: A novel, efficacious cephemderivative, FR193879. Bioorg Med Chem Lett 2004; 14: 2627-31.
76. Marash, M., Kluev, E.: WO05048912A2 and WO05048912A3 (2005).
77. Vertesy, L., Kurz, M., Markus, A., Seibert, G.: US20006077830 (2000).
78. Pedrazzoli, J.: WO04089340A1 (2004).
79. De Reuse, H, Skouloubris, S, Cussac, V, Labigne, A.: US20046762051 (2004).
80. Kodama, Y, Icatlo, Jr. F, Kimura, N, Ariga, M.: US20046793921 (2004).